Teva director granted 7,242 restricted share units

Crane Rosemary A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Crane Rosemary A reported acquisition or exercise transactions in this Form 4 filing.

TEVA PHARMACEUTICAL INDUSTRIES LTD director Rosemary A. Crane received a grant of 7,242 restricted share units as equity compensation. These restricted share units were awarded on May 28, 2026 and will vest on May 28, 2027, meaning she must remain eligible through that date to receive the shares.

Each restricted share unit represents a contingent right to receive one ordinary share of Teva, or at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share. Following this award, Crane directly holds 7,242 restricted share units related to Teva ordinary shares.

Insider Trade Summary

Grant/Award: 7,242 shares

Grant/Award 1 txn

Insider Crane Rosemary A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	7,242	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 7,242 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

RSU grant size: 7,242 units Grant price per unit: $0.0000 per unit Shares underlying RSUs: 7,242 shares +3 more

6 metrics

RSU grant size 7,242 units Restricted share units granted on May 28, 2026

Grant price per unit $0.0000 per unit Equity compensation grant, no purchase price paid

Shares underlying RSUs 7,242 shares Underlying Teva ordinary shares for granted restricted share units

Total RSUs after grant 7,242 units Direct holdings following the reported transaction

Vesting date May 28, 2027 Date when RSUs vest if conditions are met

ADS to ordinary share ratio 1 ADS : 1 ordinary share Each American Depositary Share currently equals one ordinary share

Key Terms

Restricted Share Units, contingent right, Ordinary Shares, American Depositary Shares

4 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"represents a contingent right to receive, at settlement, one ordinary share or the cash value"

Ordinary Shares financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Teva (TEVA) director Rosemary A. Crane report in this Form 4?

Rosemary A. Crane reported receiving 7,242 restricted share units as equity compensation. The award relates to Teva ordinary shares and was structured as a grant, not an open-market stock purchase or sale, so it reflects compensation rather than trading activity.

How many Teva (TEVA) restricted share units were granted to Rosemary A. Crane?

She was granted 7,242 restricted share units. Each unit is tied to one Teva ordinary share, or the cash value of one share at settlement, giving her a contingent equity interest that depends on vesting and the company’s share value at that time.

When do Rosemary A. Crane’s Teva (TEVA) restricted share units vest?

The restricted share units granted to Rosemary A. Crane vest on May 28, 2027. Vesting means that on that date, if conditions are met, she becomes entitled to receive Teva ordinary shares or the equivalent cash value for each vested unit.

What does each Teva (TEVA) restricted share unit represent for Rosemary A. Crane?

Each restricted share unit represents a contingent right to receive one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. This aligns her compensation with shareholder value at settlement.

Are Rosemary A. Crane’s Teva (TEVA) restricted share units the same as American Depositary Shares?

The underlying security is Teva ordinary shares, which may be represented by American Depositary Shares. Each American Depositary Share currently represents one ordinary share, so one vested restricted share unit corresponds economically to one ADS at the time of settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crane Rosemary A

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	05/28/2026		A		7,242		(2)	(2)	Ordinary Shares(3)	7,242	$0	7,242	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Rosemary A. Crane	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)